Biomarkers in Anderson–Fabry Disease
Simonetta, I., et al. Biomarkers in Anderson–Fabry Disease. International Journal of Molecular Sciences. 2020,21,8080;doi:10.3390/ijms21218080
- Categories
- Reviews
Simonetta, I., et al. Biomarkers in Anderson–Fabry Disease. International Journal of Molecular Sciences. 2020,21,8080;doi:10.3390/ijms21218080
de Gonzalo-Calvo, D. et al. Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. Theranostics 2020;10(19): 8665-8676. doi: 10.7150/thon.46123
Murphy, D., et al. Angiogenic and Immunomodulatory Biomarkers in Axitinib-treated Patients with Advanced Renal Cell Carcinoma. Future Oncology (Epub ahead of print) 10.2217/fon-2020-0212
Hwang, M., et al. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era. Poster session presented at: United Sstates and Canadian Academy of Pathology (USCAP) 109th Annual Meeting 2020 FEB 29- MAR 5, Los Angeles, CA
Satake, E. et al., Circulating miRNAs profile and risk of end-stage renal disease in type 1 diabetes. Abstract presented at: American Society of Nephrology (ASN). 2017 Nov; New Orleans, LA.
Pierard, L., et al. Involvement of Angiogenin in Sunitinib Resistance in Human renal Cell Carcinoma. The Journal of Urology2017; 197, No. 4S, Supplement e966.
Hamaldi, I., et al. LIM1 Oncogene as a New Therapeutic Target in Advanced Human Renal Cell Carcinoma, The Journal of Urology2017; 197, No. 4S, Supplement e793
Page last updated April 14, 2021